Using the allosteric CaSR inhibitor NPS 2143, bone metastatic RCC cells were no longer responsive to calcium (cell migration: p = 0.078, proliferation p = 0.154), which confirmed the effect of calcium via the CaSR (Figure 3A, B). The gene discussed is CASR; the disease is renal cell carcinoma.